Pseudoprogression and Immune-Related Response in Solid Tumors

被引：723

作者：

Chiou, Victoria L. ^{[1
]}

Burotto, Mauricio ^{[1
]}

机构：

[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 31期

关键词：

ADVANCED MELANOMA; ANTI-PD-L1; ANTIBODY; CLINICAL ACTIVITY; PHASE-I; CANCER; SAFETY; NIVOLUMAB; IPILIMUMAB; TRIAL; GUIDELINES;

D O I：

10.1200/JCO.2015.61.6870

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3541 / +

页数：5

共 22 条

[1] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[2] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[3] Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases [J].

Di Giacomo, Anna Maria ;

Danielli, Riccardo ;

Guidoboni, Massimo ;

Calabro, Luana ;

Carlucci, Dora ;

Miracco, Clelia ;

Volterrani, Luca ;

Mazzei, Maria Antonietta ;

Biagioli, Maurizio ;

Altomonte, Maresa ;

Maio, Michele .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) :1297-1306

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Why RECIST Works and Why It Should Stay Counterpoint [J].

Fojo, Antonio T. ;

Noonan, Anne .

CANCER RESEARCH, 2012, 72 (20) :5151-5157

[6] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Wolchok, Jedd D. ;

Hersey, Peter ;

Joseph, Richard W. ;

Weber, Jeffrey S. ;

Dronca, Roxana ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Zarour, Hassane ;

Joshua, Anthony M. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Algazi, Alain ;

Mateus, Christine ;

Boasberg, Peter ;

Tumeh, Paul C. ;

Chmielowski, Bartosz ;

Ebbinghaus, Scot W. ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144

[7] Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J].

Herbst, Roy S. ;

Soria, Jean-Charles ;

Kowanetz, Marcin ;

Fine, Gregg D. ;

Hamid, Omid ;

Gordon, Michael S. ;

Sosman, Jeffery A. ;

McDermott, David F. ;

Powderly, John D. ;

Gettinger, Scott N. ;

Kohrt, Holbrook E. K. ;

Horn, Leora ;

Lawrence, Donald P. ;

Rost, Sandra ;

Leabman, Maya ;

Xiao, Yuanyuan ;

Mokatrin, Ahmad ;

Koeppen, Hartmut ;

Hegde, Priti S. ;

Mellman, Ira ;

Chen, Daniel S. ;

Hodi, F. Stephen .

NATURE, 2014, 515 (7528) :563-+

[8] Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. [J].

Hodi, F. Stephen ;

Sznol, Mario ;

Kluger, Harriet M. ;

McDermott, David F. ;

Carvajal, Richard D. ;

Lawrence, Donald P. ;

Topalian, Suzanne Louise ;

Atkins, Michael B. ;

Powderly, John D. ;

Sharfman, William Howard ;

Puzanov, Igor ;

Smith, David C. ;

Leming, Philip D. ;

Lipson, Evan J. ;

Taube, Janis M. ;

Anders, Robert ;

Horak, Christine E. ;

Kollia, Georgia ;

Gupta, Ashok Kumar ;

Sosman, Jeffrey Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[9]

Hodi FS, 2014, J CLIN ONCOL, V32, p5s

[10] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial [J].

Motzer, Robert J. ;

Rini, Brian I. ;

McDermott, David F. ;

Redman, Bruce G. ;

Kuzel, Timothy M. ;

Harrison, Michael R. ;

Vaishampayan, Ulka N. ;

Drabkin, Harry A. ;

George, Saby ;

Logan, Theodore F. ;

Margolin, Kim A. ;

Plimack, Elizabeth R. ;

Lambert, Alexandre M. ;

Waxman, Ian M. ;

Hammers, Hans J. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) :1430-1437

← 1 2 3 →